Ascendis Pharma (ADR) (ASND)
Builds and commercializes rare-endocrinology medicines through the TransCon prodrug platform.
Something off on this page? Send us feedback.
Develops and commercializes TransCon-based rare-endocrinology medicines, led by SKYTROFA, YORVIPATH, and YUVIWEL. Direct sales focus on the United States and Europe, with partners covering selected geographies and therapeutic areas; the business depends on regulatory outcomes, a limited product set, and third-party manufacturing and distribution.
Develops and commercializes rare-endocrinology medicines built on the TransCon long-acting prodrug platform. The direct portfolio comprises SKYTROFA for growth hormone deficiency, YORVIPATH for adult hypoparathyroidism, and YUVIWEL for pediatric achondroplasia, all managed within one business unit.
Retains direct commercial focus in the United States and Europe while using partners in Greater China and selected therapeutic areas or geographies. Applying one platform across the portfolio has carried the business from clinical development into a three-brand commercial operation, with YORVIPATH providing the largest share of recent product revenue.
Depends on regulatory outcomes, commercialization of a limited product set, and third-party manufacturing, distribution, and services. YUVIWEL's accelerated approval may depend on confirmatory verification of clinical benefit.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 16, 2026 | UBS | Reiterate | Rating: —Target: $345 | Target: $344 |
| Sep 15, 2026 | Raymond James | Downgrade | Target: — | Target: $287 |
| Sep 10, 2026 | H.C. Wainwright | Target | Target: $345 | Target: $344 |
| Sep 1, 2026 | Oppenheimer | Reiterate | Rating: —Target: $262 | Target: $312 |
| Sep 1, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $275 | Target: $273 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $928.4M · Total debt $514.5M · Total assets $2.61B · Shareholders' equity $1.64B
- Revenue
- $394.4M
- Operating income
- $72.5M
- Net income
- $240.6M
Reported in EUR, converted at the latest exchange rate
No dividends on record.
| Institutions | 107.97% | 66.92M ADS | |
|---|---|---|---|
| 334 holders · as of Jun 30, 2026 | |||
| Insiders | 0.83% | 514.5K ADS | |
| 11 holders · as of Sep 3, 2026 | |||
| Strategic holders | 8.58% | 5.32M ADS | |
| 2 holders · as of May 15, 2026 | |||
| Adds to | 117.38% | ||
61.98M ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 117.38%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 16.59% | 10.28M ADS | as of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 10.90% | 6.75M ADS | as of Jun 30, 2026 |
Avoro Capital Advisors LLCInstitution | 8.25% | 5.11M ADS | as of Jun 30, 2026 |
Westfield Capital Management Co LPInstitution | 7.74% | 4.80M ADS | as of Jun 30, 2026 |
Janus Henderson Group PLCStrategic | 6.00% | 3.72M | filed May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 8, 2026 | Mads Bodenhoff | officer: SVP & PAO | −3,000 | $270.19 |
| Sep 2, 2026 | Lars Holtug | director | −236 | $264.13 |
| Aug 14, 2026 | Jean Jacques Bienaime | director | +2,000 | $246.33 |
| Jun 2, 2026 | Scott Thomas Smith | officer: EVP & Chief Financial Officer | +100 | $219.00 |
| May 29, 2026 | Scott Thomas Smith | officer: EVP & Chief Financial Officer | +250 | $223.32 |
- BioMarin
Approved achondroplasia incumbent with daily VOXZOGO
- AstraZeneca (ADR)
Late-stage PTH-receptor challenger in adult hypoparathyroidism
- Novo Nordisk (ADR)
Weekly and daily growth-hormone rival across pediatric and adult GHD
- M.B.X. Biosciences
Once-weekly PTH prodrug advancing toward Phase 3
- Pfizer
Weekly pediatric and daily growth-hormone franchise
- BridgeBio Pharma
Late-stage oral FGFR3 inhibitor for achondroplasia
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Ascendis Pharma (ADR) | $237.96 | +0.16% | $14.76B | 18.1 | 34.0 | 12.2 | +108.2% |
| BioMarin | $64.52 | +0.71% | $12.38B | 164.3 | 10.5 | 3.6 | +20.0% |
| AstraZeneca (ADR) | $168.43 | +0.19% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Novo Nordisk (ADR) | $39.36 | −1.11% | $176.83B | 9.9 | 16.2 | 3.5 | +1.3% |
| M.B.X. Biosciences | $61.59 | +1.07% | $2.90B | — | — | — | — |
| Pfizer | $27.77 | +0.09% | $158.10B | 36.7 | 9.9 | 2.5 | +2.6% |
| BridgeBio Pharma | $69.22 | +3.97% | $13.04B | — | — | 18.8 | +120.4% |
| Median | 30.9 | 13.2 | 3.6 | +6.4% |